lower tp speak
compani week matter
lower target price follow earn adjust
model follow earn follow-up call compani
chang lead us lower target price
modestli reduc sale estim vivitrol aristada also
increas expens assumpt given on-going spend
pipelin expect increas sg late-stag asset
success make market
maintain outperform rate enter catalyst-rich period
ad pdufa date januari
data also data
mid-lat
ep move
main risk view stock disappoint commerci
execut key market product vivitrol aristada
neg news pipelin especi
expect signific volatil come week risk/reward
skew upsid target price base blend
dcf rel valuat use wacc along
perpetu growth forecast dcf valuat appli
multipl estim forward revenu deriv rel
valuat base recent convers investor believ
expect fairli low go ad
maintain probabl success clear posit outcom could
drive stock even beyond target price neg
outcom could push back mid-high look broadli
convers suggest us clear posit news
could move stock close neg news
three could drive stock
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
plc global biopharmaceut compani research
develop commerci partner
pharmaceut product design address central
price oct rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base vivitrol
schizophrenia franchis gener peak combin sale
blue sky valuat base dcf driven
wacc along termin growth rate thereaft
grey sky valuat base vivitrol gener
peak sale sale grey sky
valuat base dcf driven wacc along
 close
opportun speak member ir team follow
confer call gain addit clariti dynam around certain product
well bake expect go forward
summar compani answer question
 led vivitrol sale growth come volum growth
vivitrol gross-to-net rebat increas patient use
drug medicaid impact averag net sell price
 think vivitrol growth long-term
sale need hit bottom rage guidanc
year think us opioid epidem polici work
go regard addict could signific role drive growth want
help build comprehens treatment solut opioid addict get
littl bit experi sell vivitrol give guidanc februari
anticip continu growth futur
 dynam around below-consensu aristada sale launch
initio addit sale
larg driven mix sale medicaid/medicar
side gross-to-net rebat continu trend upward initio launch go well
launch includ sampl tri get product
mani peopl possibl result sampl commerci sale initio
minim peopl get experi drug see benefit
sampl includ sg
overal benefit initio launch impact bring us full-
year guidanc rang
 penetr rate lai class europ us
lai use much europ exampl spain highest adopt rate
compar us lai market gener continu grow
low double-digit rate hope go forward due overal market growth
aristada famili complet anticip bigger slice pie
 vivitrol volum ytd unit gross-to-net project
increas volum yoy flat sequenti net sale increas
impact gross-to-net rebat vs taken price increas
sinc dec gener price pressur us gross-to-net rebat
increas number peopl use vivitrol medicaid
increas advers impact sale expect rebat around
vivitrol go forward furthermor depend mix could increas
growth come medicaid side busi
 could give us broader framework expens growth next year
regard differ scenario around approv pipelin drug
cog depend volum rel high margin aristada
 spend phase program finish except expect
increas expens fact lot depend whether continu develop
alon vs partner anoth compani exist program spend
continu part studi continu pay
spend inexpens year anticip complet dose
escal get go combin expens significantli increas
wouldnt anticip spend go rather base
big becom
sg side see big movement plan bring
specialist salespeopl roll-out depend approv anticip
increas spend mid-year launch dea
review point would see higher expens sale moreov
look good would file launch see sale expens
around
increas spend one one sale
rel effici expens year bulk
commerci see expens increas go forward
go launch cycl time feb come around idea
expens look like gener would signific spend
posit scenario drug approv
 mileston payment
next one approv potenti end
summar alkss answer analyst question compani
earn confer call
 discontinu rate blind basi track in-lin
discontinu rate in-lin model
 think patient studi get zyprexa may outlier
regard weight gain patient tend discontinu therapi
regard discontinu tend pick site center abil
keep peopl studi model follow-up type studi
 proport tecifidera patient actual think
view patient get gi toler challeng begin
stabl tecifdera seem like patient switch
expert current see gi discontinu rate
 subq dose quick escal expect see
data
ye would expect data still experi see actual
regimen would infrequ dose may compar
control see well work vs iv therefor everyth driven speed
enrol get inform fairli quickli
 regard announc sale forc expans aristada
overlap either potenti sale forc
ye account
 sinc adcom soon would abl share us info
exchang fda seen brief document
expect type question fda may ask
import point adcom substanti evid
efficaci question committe comfort new studi design
feel quit strongli efficaci data new studi designs/method analysi
use confirm data second point fda conven psychopharmacolog
adcom drug safeti adcom due opioid system modul
question issu launch compound addict potenti
midst opioid crisi right label info set
 said look introduc new candid clinic
small molecul biolog therapeut categori look
oncolog other
disclosur today histor strength small
molecul drug discoveri get stronger stronger augment
trigger program increas interest expertis
biolog small larg molecul develop interest
oncolog especi may foundat certain combin also
deep expertis psychiatri name progress
 data sent fda alreadi made public
addit data nda file
ad phase studi human abus potenti data
seen public public also long-term data might
seen gener though data sent fda seen
public line previou data
 phase studi studi scenario adcom
recommend drug approv would continu develop usual adcom
binari yes/no event regard recommend would
scenario path could continu could think beyond
happen adcom
interest explor quantit clinic featur
differ might captur classic madr ham-d scale
committe say need anoth studi data abil tune studi
order provid data caveat studi major depress
disord activ agent often separ placebo due high placebo
 head adcom shouldnt fda make request
made rtf letter request multipl trial
actual fda didnt request multipl trial misunderstand
factual defici sinc clear review
 relat roch put singl agent monotherapi respons effect
confirm monotherapi dose expans
renal melanoma correct
interest roch data sinc set minim
expans treg abl recapitul singl agent efficaci
get monotherapi efficaci would foundat piec explor combin
therapi ye monotherapi expans renal melanoma
 strateg lai make inject buprenorphin would easi
didnt
term lai addict major impedi new drug develop
launch treatment system outsid medic system new agent
adopt rapidli use continu fight way success vivitrol
interest long act inject buprenorphin product even see
launch slow growth area well plenti time play choos
 would clinic meaning commerci meaning benefit
weight gain outlier weight gain commerci relev trial
mean weight chang patient gain bodi weight import
import shape weight gain curv flatten slope
weight gain time key accord clinician basic meaning endpoint
lack weight gain short period
 doesnt get first tri would phase studi
make call say believ
strong case well see wont keep go studi wouldnt make
sens scenario committe disapprov
 vivitrol see opioid bill
much continu opportun vivitrol growth hard predict
slope give annual guidanc februari
 question committe surpris anyth els
awar
adcom proceed expect see final brief
everyon els well look forward
 hope achiev head-to-head aristada studi
year ago present data show sustenna patient switch aristada
patient switch good respons initio approv want run studi
meaning start patient initio hospit discharg
two-month dose would power primari comparison intergroup
look baselin patient group compar result
certain time point month two month etc also give us opportun parallel
way look rel efficaci two medicin dont know give us
label indic would certainli give us inform lot opinion leader
folk commun interest see
 commerci prep key catalyst adcom
pdufa date lastli size footprint
wont hire salesforc think approv receiv
approv fortun drug would go month
schedul would operation launch summer lot work gone
educ peopl good drug well prepar launch well
commerci footprint depend approv
 vivitrol attribut im data pick
dont look week week growth dont over-interpret two-to-thre week
trend basic driver polici shift toward lai antagonist money
flow fight inertia broken treatment system remain
optimist chip away broken system vivitrol
charl martineau pm univers toronto competitor treat mdd and/or trd
ahead adcom pdufa date jan provid overview
current competitor drug treat major depress disord mdd well possibl futur competitor
still develop mdd treatment-resist depress trd
figur current drug indic mdd
norepinephirin
increas poor
redos
increas everi
day respons
increas
day initi target
week
stimul littl sexual
may induc seizur
person seizur disord
higher risk arrythmia
compar ssri
effect norepinephrin
serotonin
increas
partial respons week
associ
higher risk irregular
increas everi
day respons
serotonin
increas increment
maintain week
increas
sedat low dose
increas everi
day
tricycl
increas everi
day respons
fda-approv mani
increas everi
day respons
less nausea gi distress
occasion
increas everi
day respons
week maintain
week next increas
fda-approv anxieti
safe patient
previous heart attack
higher rate psychiatr side
effect diarrhea compar
ssri
one week
two week
week increas
higher dose expens
charl martineau pm univers toronto figur select pipelin drug develop mdd and/or trd
mechan action
mdd/trd unless
dopamin
lead euphoria
glyxin
receptor make possibl
analges less
chronic stress
ideat adjunct oral
potenti addict
potenti neurotox
adjunct
must infus
intraven may
potenti neurotox
phase top-line result
sublingu adjunct
opioid high potenti
addict potenti
gaba-a receptor
oral neurosteroid
could need
taken daili
oral daili rapid onset
phase mdd result
us million unless otherwis state
figur guidanc compar cs consensu estim
incom tax effect relat reconcil item
greater previou expect
us million unless otherwis state
us thousand unless otherwis state
us thousand unless otherwis state
research develop revenu
amort acquir intang asset
chang fair valu conting consider
average number common share out non-gaap
 sale
sg sale
compani mention price
